No association between migraine and breast cancer risk
the ONA take:
According to a new study published in the Journal of the National Cancer Institute, researchers at Harvard University Medical School in Boston, Massachusetts, have found that there is no associated between migraines and risk of breast cancer.
For the studies, researchers analyzed four other studies that included over 100,000 women actually found that migraines may decrease the risk of breast cancer, but researchers note that this finding may be due to study design rather than a real association.
The theory that there was a link between migraines and risk of breast cancer comes up from the notion that both arise from increased sex hormone levels. When the research team analyzed the levels of sex hormones in about 2,000 premenopausal women who experience migraines, the researchers found no link between the two.
According to the Migraine Research Foundation, approximately 18% of American women and 6% of American men experience migraines. A migraine is a severe headache that is often accompanied by sensitivity to light and sound, nausea, visual disturbances, and vomiting. A migraine can last anywhere between 4 hour and 3 days.
There is no associated between migraines and risk of breast cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|